Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026
Greenwich LifeSciences announced preliminary Phase III FLAMINGO-01 trial data showing statistically significant increased immune response (delayed-type hypersensitivity reactions) in non-HLA-A*02 breast cancer patients treated with GLSI-100, an immunotherapy targeting HER2-expressing cancers. Early analysis suggests a 70-80% reduction in breast can…